Quick answer
As read on 17 November 2026: FDA's regulation listing 503A bulk substances does not name BPC-157; FDA's July 2026 briefing document says no USP or NF monograph applies, that it is not a component of an approved drug and that the criteria "weigh against" listing; HHS published a draft, non-binding enforcement discretion notice on 30 October 2026 whose Appendix A names BPC-157; and WADA's 2026 List names it under S0. This summarizes documents only and gives no legal conclusion or advice.
This article reads the primary documents that name BPC-157 in 2026 and states what each says, with the date it was read (17 November 2026). The documents are two FDA pages on bulk drug substances, an FDA briefing document and event page for the July 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting, a Federal Register notice and policy document from the Department of Health and Human Services (HHS), and the World Anti-Doping Agency (WADA) 2026 Prohibited List. Law-firm and news summaries were not used. The article draws no legal conclusion, gives no advice and does not say whether any activity is lawful; for that, consult the agencies or qualified counsel. The broader library overview is research peptide legal status in the US, and the compound itself is covered in the BPC-157 research overview.
V8 products are labeled for laboratory research use only. This article describes documents and states no legal conclusion.
What FDA's section 503A page says
FDA's page "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act" (read 17 November 2026) states that state-licensed physicians and pharmacists that compound under section 503A "may only compound drug products using bulk drug substances" that comply with an applicable USP or NF monograph if one exists; are components of FDA-approved drug products if no monograph exists; or appear on FDA's 503A bulks list if neither applies. The regulation that holds that list, 21 CFR 216.23(a) (eCFR, read 17 November 2026), names six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide. BPC-157 is not among them. The same page says FDA solicited nominations in 2015 and is evaluating them with the Pharmacy Compounding Advisory Committee and the U.S. Pharmacopeia Convention.
What the FDA briefing document says about BPC-157
FDA's briefing document for the July 2026 PCAC meeting (fda.gov/media/193343/download; evaluation dated 11 May 2026) is titled "FDA Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (Free Base) and BPC-157 Acetate)." It states that "there is no applicable United States Pharmacopeia (USP) or National Formulary (NF) drug substance monograph for BPC-157 (free base) or its acetate form, and neither is a component of an FDA-approved drug," and that BPC-157 "is marketed in the United States as an ingredient in dietary supplement products formulated as oral capsules and tablets," with no USP dietary supplement monograph. Its conclusion states: "a balancing of the criteria weighs against BPC-157 (free base) and BPC-157 acetate being placed on that list." Among its reasons, the document says each form "is considered not well-characterized from the physical and chemical characterization perspective," citing inconsistent naming and missing data on peptide-related impurities and aggregates, microbial quality and bacterial endotoxins. The cover pages state that FDA "will not issue a final determination" until the advisory committee process has been considered.
The agenda document for the meeting (fda.gov/media/193342/download) records that the nominations for BPC-157, from two nominators, were withdrawn by the nominators, and that "FDA is electing to proceed with the presentation" of BPC-157 to the committee.
What FDA's Category 2 page says
FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (read 17 November 2026) has a section titled "Bulk drug substances nominated but withdrawn," described as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators." BPC-157 is listed there, with this FDA text: "Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration."
The July 2026 advisory committee meeting
A Federal Register notice of 16 April 2026 (91 FR 20465, document 2026-07361, docket FDA-2025-N-6895) announced that the PCAC would meet on 23 and 24 July 2026. FDA's agenda document lists BPC-157-related substances (free base and acetate) first on the 23 July agenda, ahead of KPV, TB-500 and MOTs-C, and FDA's event page says advisory committees "make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so." This article did not locate a vote record or minutes on fda.gov. The only description of the vote found is in the HHS policy document, quoted below.
The HHS notice and policy document
The Federal Register notice (91 FR 68526, document 2026-22192, docket HHS-OASH-2026-0496, published 30 October 2026) announces the availability of a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." It says HHS "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A," that the draft policy "does not establish any rights for any person and is not binding on HHS or the public," and that HHS "may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises." Appendix A of the linked policy document lists six substances: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.
Appendix B of the policy document states of BPC-157: "BPC-157 (free base) and BPC-157 acetate were in Category 2 from September 2023 until April 22, 2026, and neither the placement nor the removal changed their status under section 503A; Center for Drug Evaluation and Research (CDER) recommended against listing either form, and the Pharmacy Compounding Advisory Committee (PCAC) voted in favor of inclusion." It gives three justifications (documented historical use, a lot-specific certificate of analysis from an FDA-registered facility, and policy conditions on lot-level testing, single-ingredient products and MedWatch reporting) and says enforcement discretion for BPC-157 acetate is appropriate for four listed routes (subcutaneous, intramuscular, oral and topical) when the product is "compounded from API accompanied by a certificate of analysis (CoA) meeting the conditions of this policy."
The policy document also states the Secretary's determination that the policy "will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk" (the sentence continues beyond this quotation). It is quoted as the document words it and is not interpreted here. The Federal Register notice itself does not mention research-use-only materials.
The WADA 2026 Prohibited List
The 2026 List states that it "shall come into effect on 1 January 2026." Section S0, "Non-approved substances," is labeled "prohibited at all times (in- and out-of-competition)." It covers pharmacological substances not addressed by other sections and with no current approval by a governmental regulatory health authority for use as a medicine in people (paraphrased here) and states that the class covers "many different substances including but not limited to BPC-157, 2,4-dinitrophenol (DNP)," and others. The List's own heading says all prohibited substances in S0 are Specified Substances. WADA's page for the List (read 17 November 2026) says the List and its Q&As "can also be consulted under the Athlete and Support Personnel section" of its site.
Published analytical work exists on detection. Cox and colleagues (2017) describe BPC 157 in confiscated vials and report a urine method with a limit of detection of 0.1 ng/mL. A 2025 systematic review (Vasireddi et al.) states in its abstract that BPC-157 lacks FDA approval and that its use is banned in professional sports, and that of 36 studies included, 35 were preclinical and 1 was clinical.
Where BPC-157 appears across the documents
The table records only what the documents above say, as read on 17 November 2026. "Not named" means the compound does not appear in that document's text.
| Document | Issuer | What it says about BPC-157 |
|---|---|---|
| 21 CFR 216.23(a) | FDA (regulation) | Not among the six listed substances |
| FDA 503A page | FDA | Page states the three routes for bulk substances; does not discuss BPC-157 individually |
| Briefing document (evaluation dated 11 May 2026) | FDA | No USP/NF monograph; not a component of an FDA-approved drug; criteria "weigh against" listing |
| Category 2 page | FDA | Listed under substances nominated but withdrawn |
| Policy document, Appendix A and B | HHS | Listed; Category 2 from September 2023 to 22 April 2026; PCAC "voted in favor of inclusion" |
| 2026 Prohibited List, S0 | WADA | Named as an example in S0; prohibited at all times |
A timeline of the dates in this article
| Date | Event | Source |
|---|---|---|
| September 2023 | Start of the Category 2 period stated for BPC-157 | HHS policy document |
| 1 January 2026 | WADA 2026 Prohibited List takes effect | WADA |
| 16 April 2026 | Federal Register notice of the July PCAC meeting (91 FR 20465) | Federal Register |
| 22 April 2026 | End of the Category 2 period stated for BPC-157 | HHS policy document |
| 11 May 2026 | Date of FDA evaluation of BPC-157-related substances | FDA briefing document |
| 23 July 2026 | PCAC meeting day on which BPC-157 was on the agenda | FDA agenda document |
| 30 October 2026 | HHS notice published, 91 FR 68526 | Federal Register |
| 17 November 2026 | Date these documents were read for this article | — |
Reading dates and drafts correctly
Three habits help with regulatory material. First, check the document type: the HHS notice announces a draft policy and says the policy is not binding. Second, record the access date; the documents above can be revised and this article reflects only what was read on 17 November 2026. Third, note who issued each document, because FDA, HHS and WADA are separate bodies and each speaks only for itself. Where the FDA page and the HHS document describe the Category 2 history in different words, both are reported and neither is reconciled here. For laboratory records, identity and purity documentation is covered in how to read a COA, BPC-157 purity testing and the COA page.
Limits of this article
This article does not cover state law, controlled-substance scheduling, customs and import rules, or foreign regulation, and it does not assess whether any seller or activity complies with any law. FDA's evaluation was read for its introduction, nomination notes and conclusions, not every page. Related reading: vetting a research peptide supplier, what are research peptides and how research peptides are shipped. The product page for BPC-157 lists specifications for laboratory research use only.
Frequently asked questions
Is BPC-157 named in FDA's regulation listing bulk substances for 503A compounding?
No. 21 CFR 216.23(a), as read on 17 November 2026, names six substances and BPC-157 is not one of them.
What does FDA's briefing document say about a USP monograph for BPC-157?
It states there is no applicable USP or NF drug substance monograph for BPC-157 or its acetate form, and that neither is a component of an FDA-approved drug.
What was FDA's conclusion in the briefing document?
That "a balancing of the criteria weighs against" placing BPC-157 (free base) and BPC-157 acetate on the 503A bulks list, as of the evaluation dated 11 May 2026.
Where does FDA's Category 2 page list BPC-157?
Under "Bulk drug substances nominated but withdrawn," as read on 17 November 2026.
What did HHS publish on 30 October 2026?
A Notice of Availability (91 FR 68526) for a draft enforcement discretion policy on 503A compounding using certain peptide bulk drug substances. Appendix A of the policy document lists BPC-157 among six peptides.
Is the HHS policy binding?
The notice states that the draft policy does not establish any rights for any person and is not binding on HHS or the public, and that HHS may revisit it.
What does the policy document say about the advisory committee vote?
Appendix B states that the PCAC "voted in favor of inclusion" for BPC-157. This article did not find a separate FDA vote record.
What does the WADA 2026 List say about BPC-157?
It names BPC-157 as an example under S0, Non-approved substances, which is prohibited at all times, in force from 1 January 2026.
Does this article say whether anything is legal?
No. It reports what documents state, with dates, and draws no legal conclusion.
Where can the primary documents be read?
The Federal Register notice 2026-22192, FDA's 503A and Category 2 pages and July 2026 PCAC materials, 21 CFR 216.23 on eCFR, the HHS policy PDF and the WADA Prohibited List PDF, listed in the references.
Related reading: Research Peptide Documents in 2026: HHS, FDA and WADA Read, Tirzepatide: FDA, HHS and WADA Documents Read, BPC-157 and TB-500: US Regulatory Documents in 2026, PT-141 US Regulatory Status: A Primary-Source Summary.
References
- Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability). Federal Register. 2026 Oct 30;91:68526-68527. Document 2026-22192. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances (read 17 November 2026).
- Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy document with Appendices A and B). https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf (read 17 November 2026).
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act; and Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov (both read 17 November 2026). 21 CFR 216.23, ecfr.gov (read 17 November 2026).
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (event page) and FDA Briefing Documents, fda.gov/media/193342/download, /193343/download and /193349/download (read 17 November 2026).
- World Anti-Doping Agency. The 2026 Prohibited List, World Anti-Doping Code International Standard. In force 1 January 2026. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (text read 17 November 2026).
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. doi:10.1177/15563316251355551
- Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H by LC-MS/MS. Drug Test Anal. 2017;9(10):1490-1498. doi:10.1002/dta.2152
